The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Tandem Diabetes Care Inc (NASDAQ: TNDM) was $22.48 for the day, down -0.62% from the previous closing price of $22.62. In other words, the price has decreased by -$0.62 from its previous closing price. On the day, 0.6 million shares were traded. TNDM stock price reached its highest trading level at $22.79 during the session, while it also had its lowest trading level at $22.17.
Ratios:
Our analysis of TNDM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.44. In the meantime, Its Debt-to-Equity ratio is 3.38 whereas as Long-Term Debt/Eq ratio is at 3.22.
On September 08, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $22.Oppenheimer initiated its Outperform rating on September 08, 2025, with a $22 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 11 ’25 when Sheridan John F bought 10,000 shares for $10.23 per share. The transaction valued at 102,318 led to the insider holds 106,327 shares of the business.
Vosseller Leigh bought 13,720 shares of TNDM for $149,404 on Aug 08 ’25. The EVP & CHIEF FINANCIAL OFFICER now owns 25,580 shares after completing the transaction at $10.89 per share. On Mar 07 ’25, another insider, Kyrillos Jean-Claude, who serves as the EVP & Chief Operating Officer of the company, bought 10,538 shares for $18.12 each. As a result, the insider paid 190,966 and bolstered with 10,538 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 1524196992 and an Enterprise Value of 1659270016. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.51 while its Price-to-Book (P/B) ratio in mrq is 11.46. Its current Enterprise Value per Revenue stands at 1.648 whereas that against EBITDA is -23.846.
Stock Price History:
The Beta on a monthly basis for TNDM is 1.69, which has changed by -0.39045554 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, TNDM has reached a high of $38.28, while it has fallen to a 52-week low of $9.98. The 50-Day Moving Average of the stock is 21.69%, while the 200-Day Moving Average is calculated to be 30.84%.
Shares Statistics:
TNDM traded an average of 2.07M shares per day over the past three months and 1629650 shares per day over the past ten days. A total of 67.77M shares are outstanding, with a floating share count of 67.09M. Insiders hold about 1.06% of the company’s shares, while institutions hold 112.45% stake in the company. Shares short for TNDM as of 1765756800 were 8176917 with a Short Ratio of 3.94, compared to 1763078400 on 8787092. Therefore, it implies a Short% of Shares Outstanding of 8176917 and a Short% of Float of 16.690001.
Earnings Estimates
The market rating for Tandem Diabetes Care Inc (TNDM) is a result of the insights provided by 20.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.2 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.5 and -$3.32 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$0.97, with 22.0 analysts recommending between -$0.58 and -$2.39.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 19 analysts. It ranges from a high estimate of $281.86M to a low estimate of $271.43M. As of. The current estimate, Tandem Diabetes Care Inc’s year-ago sales were $282.65MFor the next quarter, 19 analysts are estimating revenue of $248.8M. There is a high estimate of $261.4M for the next quarter, whereas the lowest estimate is $232.28M.
A total of 23 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $1.01B, while the lowest revenue estimate was $995.78M, resulting in an average revenue estimate of $1B. In the same quarter a year ago, actual revenue was $940.2MBased on 23 analysts’ estimates, the company’s revenue will be $1.1B in the next fiscal year. The high estimate is $1.14B and the low estimate is $1.07B.
